article
Issue #3 2016 – Digital edition
In this issue: Biosimilars, Regulation, Packaging, Microfluidics, Microbiology, PAT, Antibiotic Resistance, and much more...
List view / Grid view
Formulation
article
Biosimilars – future prospects
Biologically-derived drugs, such as proteins, peptides and monoclonal antibodies (mABs), are playing an increasingly important role in global healthcare. It was recently reported that mAB therapeutics sell for over $50 billion globally. However, one of the major downsides of biological therapeutics is their significantly greater costs compared with small molecule…
article
PAT Series: Recent achievements in NIR-based on-line monitoring of lyophilisation processes
30 June 2016 | By Adrian Funke - Bayer Pharma AG / Reinhard Gross, Stephan Tosch and Albert Tulke - Bayer Technology GmbH
Process analytical technology (PAT), namely near-infrared (NIR) and Raman spectroscopy, has already been shown to be a useful tool for monitoring, analysing and optimising the complex process of lyophilisation. The latter process is especially challenging in the case of biopharmaceutical formulations due to the instability of active ingredients, leading to…
news
Pfizer invests big in biosimilar production in China
28 June 2016 | By Victoria White, Digital Content Producer
Pfizer is to invest $350 million in the development of a state-of-the-art Global Biotechnology Centre in the Hangzhou Economic Development Area...
news
Study finds biosimilar switching not suitable for all patients
10 June 2016 | By Victoria White, Digital Content Producer
A study presented at EULAR showed that when antibodies develop in response to the infliximab, they also cross-react with the biosimilar of infliximab...
news
Efficacy and safety of Biogen’s anti-TNF biosimilars presented at EULAR
9 June 2016 | By Victoria White, Digital Content Producer
Data demonstrating long-term comparable efficacy, safety and immunogenicity of Benepali (etanercept) and Flixabi (infliximab) have been presented at EULAR...
news
Experts analyse growth in the finished dosage market ahead of CPhI Worldwide launch
6 June 2016 | By CPhI
The new Finished Dosage Formulation (FDF) event will be the first global pharma platform dedicated to the manufacture, development and supply of finished dosage forms...
news
Infliximab biosimilar Flixabi approved in the EU
31 May 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade...
news
Researchers develop technology for printed personalised medicine
Researchers from the National University of Singapore have found a way to make personalised medicine cheaper and easier.
article
Issue #2 2016 – Digital edition
In this issue: Regulation, Oncology, Single Use, Robotics, Microbiology, PAT, Mass Spectrometry, Drug Delivery, Nanotechnology, and much more...
news
Coulter Partners has placed Dr Neil Brewis as Chief Scientific Officer and Michael Davies as VP Protein Science at F-star
Coulter Partners has placed Dr Neil Brewis as Chief Scientific Officer and Michael Davies as VP Protein Science at F-star, a leading biopharmaceutical company developing novel bispecific antibodies with a focus on immuno-oncology.
news
Future proofing – Part 2. PAT – Real time release testing of tablets
4 April 2016 | By Charles Ischi AG | Kraemer Elektronik
What requirements need to be met by a tablet testing system to guarantee a successful product release?
news
DiscoverX launches KILR™ assay platform for use in cancer immunotherapy drug development
30 March 2016 | By DiscoverX Corporation
DiscoverX Corporation has launched the KILR Retroparticles product line, providing scientists complete flexibility to develop a simple cytotoxicity assay in almost any cell line...
news
Gastric cancer treatment development shifting to mAbs
17 March 2016 | By Victoria White
The dominance of small molecules in the gastric cancer treatment space could be about to give way to monoclonal antibodies, according to GBI Research...
news
Future proofing – Part 1. Modularity and flexibility – New LAB.line tablet hardness testers
29 February 2016 | By Arwid Ischi, Charles Ischi AG | Kraemer Elektronik
What requirements need to be met by a tablet testing system to guarantee a successful product release? Is it dependable upon the testing system’s quality, speed, technology, flexibility or safety? Kraemer and Ischi explain...
